Amgen licenses GDNF protein to MedGenesis and Biovail
This article was originally published in Scrip
Executive Summary
Amgen has granted MedGenesis Therapeutix of Canada an exclusive, worldwide licence for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications.